Mereo BioPharma: Bank of America reports 3.4% stake
Bank of America reports shared voting and dispositive authority over the same 26,889,300 shares included in its 3.4% beneficial-ownership position.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Mereo BioPharma Group plc is the issuer in an amended Schedule 13G reporting Bank of America Corporation’s beneficial ownership of 26,889,300 ordinary shares, equal to 3.4% of the class. The report attributes shared voting and dispositive power over all 26,889,300 shares to Bank of America Corporation, with no sole voting or dispositive power reported. It was submitted on behalf of the corporation and its wholly owned subsidiaries. The percentage calculation uses 798,454,864 shares outstanding as of August 10, 2026, as disclosed in the issuer’s Form 10-Q.
Key Figures
Key Terms
beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which entities are included in Bank of America’s MREO ownership report?
AI-generated analysis. How Rhea-AI works. Not financial advice.